NervGen Pharma Corp Ordinary Shares NGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
-
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
-
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
Trading Information
- Previous Close Price
- $1.42
- Day Range
- $1.38–1.44
- 52-Week Range
- $1.38–6.30
- Bid/Ask
- $1.41 / $1.45
- Shares Outstanding
- 107.52M
- Market Cap
- $153.76M
- Volume/Avg
- 944,031 / 497,051
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 9
- Website
- https://www.nervgen.com
Valuation
|
Metric
|
NGEN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.47 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NGEN
|
|---|---|
Quick Ratio | 1.19 |
Current Ratio | 1.23 |
Interest Coverage | — |
Quick Ratio
NGEN
Profitability
|
Metric
|
NGEN
|
|---|---|
Return on Assets (Normalized) | −77.89% |
Return on Equity (Normalized) | −514.49% |
Return on Invested Capital (Normalized) | −520.92% |
Return on Assets
NGEN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|tq!<r% | LOCK|K?M<@ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|xdSL^zJ | LOCK|nXh&g | $83B | |||
| Moderna Inc
MRNA
| LOCK|#zVlM@ | LOCK|%%# | $80B | |||
| argenx SE ADR
ARGX
| LOCK|$?TC<r | LOCK|wJR | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^cMt@N | LOCK|b<? | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|s^HB>z | LOCK|$cLd | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$>B&^XpT | LOCK|wsBS | $28B | |||
| Incyte Corp
INCY
| LOCK|J^H>gtp | LOCK|!? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|J!M@?p | LOCK|<Ww | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%y@p@g$ | LOCK|#> | $14B |
United States